Intatacro is a drug that affects the immune system. With the main ingredient being Tacrolimus, Intatacro is used in patients after organ transplant surgery such as liver, kidney, heart.

Hemangiomas are the most common benign tumors of the liver. 5-7% of healthy people may develop hemangiomas in the liver. The incidence of hemangiomas in the liver is 6 times more common in women than in men and is often larger in size than in men. The location of hemangiomas is usually in the right liver and in the subcapsular region.

Organ transplantation in general and liver transplantation in particular is one of the greatest scientific achievements in medicine. Liver transplantation is the best treatment for end-stage liver diseases such as liver cancer, decompensated cirrhosis or liver failure. The world's first liver transplant was performed in the United States in 1963. In Vietnam, the first liver transplant was performed in 2004.

Hepatic veno-occlusive disease is caused by endothelial damage, resulting in non-thrombotic obstruction of the hepatic renal venules and hepatic sinuses rather than the hepatic vein or inferior vena cava (eg. in Budd-Chiari syndrome). The following article will clarify more about the dangers of hepatic vein occlusion or hepatic portal vein occlusion if it is not diagnosed and detected early.

Most hemangiomas are easily visible at birth, but can also appear months or years later. Hemangiomas can be found anywhere on the body, but are most common on the face, skin, head, chest or back. Small hemangiomas < 10cm in diameter are most commonly found on the skin and in children, congenital in children.

Hemangioma is a benign tumor caused by the growth (overgrowth) of blood vessels. Hemangiomas can appear anywhere in the body, most commonly at birth or within the first 6 months of a child's life.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and usually occurs in people with chronic liver disease, such as cirrhosis from hepatitis B or hepatitis C infection.